What does this research mean for the field?

Prolonged terlipressin therapy is safe and effective as a bridge to curative TIPS for HRS-AKI in nontransplant candidates. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the safety and effectiveness of prolonged terlipressin therapy as a bridge to TIPS for patients with HRS-AKI unable to undergo transplantation.

March 4, 20260 citationsOpen Access

Prolonged Terlipressin Therapy as a Bridge to Curative TIPS for HRS-AKI in a Nontransplant Candidate.

DRDeirdre ReidyCornell University AJArun JesudianCornell University MDMarion DavidInstitut de Biologie Moléculaire des Plantes

Key Points

To assess the safety and effectiveness of prolonged terlipressin therapy as a bridge to TIPS for patients with HRS-AKI unable to undergo transplantation.
Case illustration of a nontransplant candidate with HRS-AKI
Administered prolonged terlipressin therapy
Followed by transjugular intrahepatic portosystemic shunt (TIPS) for definitive treatment
Terlipressin therapy was successful in managing HRS-AKI in the patient
Patient eligible for TIPS after terlipressin treatment
Safe administration of terlipressin prior to TIPS intervention

Abstract

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a severe complication of advanced cirrhosis with high mortality and limited treatment options. Terlipressin is currently the only FDA-approved therapy for HRS, though recurrence is common upon discontinuation in patients without access to liver transplantation. Transjugular intrahepatic portosystemic shunt (TIPS) may provide definitive treatment for HRS-AKI in nontransplant candidates or in the setting of prolonged waitlists. This case illustrates the safety and success of terlipressin prior to TIPS for definitive treatment of HRS-AKI in a nontransplant candidate.

问 AI

Bookmark

View Full Paper